Psychedelic Drugmaker Definium Surges on Depression Drug Success

🇺🇸 Bloomberg (US) —

AI Summary

Definium Therapeutics Inc. shares surged by up to 60% after late-stage trial results showed promising outcomes for their experimental psychedelic treatment targeting major depressive disorders. The success marks a significant advance in depression drug development.

Definium Therapeutics Inc. shares rally as much as 60% Monday after late-stage trial data showed “groundbreaking” results in the psychedelic drug developer’s experimental treatment for major depressive disorders.

Markets Deals Health AI & Tech Definium Therapeutics psychedelic drug depression treatment clinical trial stocks major depressive disorder

Read original source →